ARL11

Summary

ARL11 (ARF like GTPase 11, HGNC:24046) is a protein-coding gene on chromosome 13q14.2, encoding ADP-ribosylation factor-like protein 11 (Q969Q4). May play a role in apoptosis.

This gene encodes a tumor suppressor related to the ADP-ribosylation factor (ARF) family of proteins. The encoded protein may play a role in apoptosis in a caspase-dependent manner. Polymorphisms in this gene have been associated with some familial cancers.

Source: NCBI Gene 115761 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hereditary neoplastic syndrome (Limited, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 51 total — 3 pathogenic
• MANE Select transcript: NM_138450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24046
Approved symbol	ARL11
Name	ARF like GTPase 11
Location	13q14.2
Locus type	gene with protein product
Status	Approved
Aliases	ARLTS1, FLJ33930
Ensembl gene	ENSG00000152213
Ensembl biotype	protein_coding
OMIM	609351
Entrez	115761

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000282026, ENST00000490932, ENST00000920918, ENST00000958145

RefSeq mRNA: 1 — MANE Select: NM_138450 NM_138450

CCDS: CCDS9419

Canonical transcript exons

ENST00000282026 — 2 exons

Exon	Start	End
ENSE00003994298	49630430	49633872
ENSE00003994313	49628507	49628615

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 92.01.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2941 / max 120.0873, expressed in 404 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135126	3.0760	399
135127	0.2181	116

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	92.01	gold quality
leukocyte	CL:0000738	91.58	gold quality
blood	UBERON:0000178	89.89	gold quality
trabecular bone tissue	UBERON:0002483	84.47	silver quality
granulocyte	CL:0000094	84.02	gold quality
bone marrow	UBERON:0002371	81.53	gold quality
thymus	UBERON:0002370	81.02	gold quality
lymph node	UBERON:0000029	76.05	gold quality
spleen	UBERON:0002106	75.96	gold quality
vermiform appendix	UBERON:0001154	74.53	gold quality
bone marrow cell	CL:0002092	71.50	gold quality
lower lobe of lung	UBERON:0008949	69.23	gold quality
caecum	UBERON:0001153	68.02	gold quality
oral cavity	UBERON:0000167	67.66	silver quality
palpebral conjunctiva	UBERON:0001812	67.56	gold quality
right lung	UBERON:0002167	67.01	gold quality
rectum	UBERON:0001052	66.26	gold quality
superficial temporal artery	UBERON:0001614	64.50	gold quality
right adrenal gland cortex	UBERON:0035827	64.35	gold quality
jejunal mucosa	UBERON:0000399	64.25	silver quality
gall bladder	UBERON:0002110	64.16	gold quality
upper lobe of lung	UBERON:0008948	63.40	gold quality
lung	UBERON:0002048	63.18	gold quality
upper lobe of left lung	UBERON:0008952	63.13	gold quality
small intestine Peyer’s patch	UBERON:0003454	62.72	gold quality
small intestine	UBERON:0002108	61.85	gold quality
smooth muscle tissue	UBERON:0001135	61.67	gold quality
esophagus mucosa	UBERON:0002469	61.60	gold quality
amniotic fluid	UBERON:0000173	61.37	gold quality
tonsil	UBERON:0002372	60.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.63

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

88 targeting ARL11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-580-3P	99.67	69.23	1841

Literature-anchored findings (GeneRIF, showing 15)

• A genetic variant of ARLTS1 predisposes patients to familial cancer. (PMID:15843669)
• the G446A in ARLTS1 gene is probably not associated with an increased risk of sporadic breast cancer, prostate cancer, melanoma, thyroid papillary cancer or laryngeal cancer (PMID:16570116)
• The study does not support the postulate that variants of ARLTS1 influence the risk of chronic lymphocytic leukemia(CLL). (PMID:16581122)
• While ARLTS1 Trp149Stop did not influence melanoma risk (OR = 0.83, 95% CI = 0.37-1.88, p = 0.65), Cys148Arg revealed a statistically significant association with an increased risk for heterozygous carriers (OR = 1.43, 95% CI = 1.05-1.95, p = 0.02) (PMID:16646072)
• we found no association of ARLTS1 polymorphisms and risk for familial chronic lymphocytic leukaemia (PMID:17391501)
• Cysteine148Arginine variant is associated with a moderately increased risk of colorectal cancer, both in sporadic and familial cases. (PMID:17449901)
• 650 transcripts expressed after restoration of ARLTS1 expression were identified in A549 cells, suggesting that pathways involved in cell survival, proliferation, signaling, and development mediate the effects of wild-type ARLTS1 in lung cancer. (PMID:17699778)
• ARLTS1 germline variants are not associated with breast, prostate, and colorectal cancer (PMID:18337727)
• A novel tumor suppressor gene [ARLTS1 (ADP-ribosylation factor-like tumor suppressor gene 1)]is found to be altered in human carcinogenesis. It is located in Chromosome 13q14.3. (PMID:18375053)
• Data show a significantly increased risk of familial OC for ARLTS1 Cys148Arg variant, which indicate that ARLTS1 may play a role in familial ovarian cancer. (PMID:19509554)
• A significantly increased risk was observed for young ovarian cancer patients with ARLTS1 Cys148Arg variant. (PMID:20067102)
• The role of the allelic variants in ARLTS1, RAD51 and MDM2 acting in the tumor suppressor, DNA repair and p53 pathways as risk factors for familial breast cancer in 147 patients displaying characteristics of familial disease, was investigated. (PMID:20358297)
• the important role of ARLTS1 Cys148Arg variant as a contributor in prostate cancer predisposition (PMID:22028916)
• A statistically significant (p = 0.0037) decrease of ARLTS1 expression in prostate cancer cases was detected. (PMID:23940804)
• ARLTS1 gene mutations can be considered as a potential predisposing factor in familial hematological malignancies (PMID:27866680)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Arl11	ENSMUSG00000043157
rattus_norvegicus	Arl11	ENSRNOG00000014653

Paralogs (30): ARF5 (ENSG00000004059), SAR1A (ENSG00000079332), ARFRP1 (ENSG00000101246), TRIM23 (ENSG00000113595), ARL6 (ENSG00000113966), ARL1 (ENSG00000120805), ARL4A (ENSG00000122644), ARL8B (ENSG00000134108), ARF3 (ENSG00000134287), ARL3 (ENSG00000138175), ARL5C (ENSG00000141748), ARF1 (ENSG00000143761), ARL8A (ENSG00000143862), SAR1B (ENSG00000152700), ARL5A (ENSG00000162980), ARF6 (ENSG00000165527), ARL5B (ENSG00000165997), ARF4 (ENSG00000168374), ARL13B (ENSG00000169379), ARL13A (ENSG00000174225), ARL10 (ENSG00000175414), ARL4D (ENSG00000175906), ARL14 (ENSG00000179674), ARL15 (ENSG00000185305), ARL17A (ENSG00000185829), ARL4C (ENSG00000188042), ARL9 (ENSG00000196503), ARL2 (ENSG00000213465), ARL16 (ENSG00000214087), ARL17B (ENSG00000228696)

Protein

Protein identifiers

ADP-ribosylation factor-like protein 11 — Q969Q4 (reviewed: Q969Q4)

Alternative names: ADP-ribosylation factor-like tumor suppressor protein 1

All UniProt accessions (1): Q969Q4

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in apoptosis. May act as a tumor suppressor.

Tissue specificity. Expressed in lung and leukocytes.

Disease relevance. Leukemia, chronic lymphocytic (CLL) [MIM:151400] A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Similarity. Belongs to the small GTPase superfamily. Arf family.

RefSeq proteins (1): NP_612459* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005225	Small_GTP-bd	Domain
IPR006689	Small_GTPase_ARF/SAR	Family
IPR024156	Small_GTPase_ARF	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00025

UniProt features (11 total): sequence variant 5, binding site 3, initiator methionine 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969Q4-F1	87.94	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 19–26; 63–67; 122–125

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, chr13q14, MARSON_BOUND_BY_FOXP3_STIMULATED, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, YOSHIMURA_MAPK8_TARGETS_UP, CHEN_METABOLIC_SYNDROM_NETWORK, CHYLA_CBFA2T3_TARGETS_UP, GOBP_INTRACELLULAR_TRANSPORT, ZNF768_TARGET_GENES, MIR4795_3P, MIR126_5P

GO Biological Process (3): hematopoietic progenitor cell differentiation (GO:0002244), intracellular protein transport (GO:0006886), vesicle-mediated transport (GO:0016192)

GO Molecular Function (4): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), plasma membrane (GO:0005886)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hemopoiesis	1
cell differentiation	1
intracellular protein localization	1
protein transport	1
intracellular transport	1
transport	1
cellular process	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1829 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL11	P2RX7	Q99572	697
ARL11	HIF1AN	Q9NWT6	589
ARL11	ARL16	Q0P5N6	540
ARL11	CDADC1	Q9BWV3	476
ARL11	ZAP70	P43403	476
ARL11	BRCA2	P51587	460
ARL11	RCBTB1	Q8NDN9	452
ARL11	CD5	P06127	436
ARL11	EBPL	Q9BY08	419
ARL11	DOCK5	Q9H7D0	415
ARL11	C17orf75	Q9HAS0	410
ARL11	DCAF10	Q5QP82	408
ARL11	ALDH3A2	P51648	405
ARL11	CHEK2	O96017	404
ARL11	PNPT1	Q8TCS8	398
ARL11	ZNF714	Q96N38	398

IntAct

11 interactions, top by confidence:

A	B	Type	Score
TRIP13	ARL11	psi-mi:“MI:0915”(physical association)	0.710
ARL11	TRIP13	psi-mi:“MI:0915”(physical association)	0.710
ARL11	SESTD1	psi-mi:“MI:0914”(association)	0.530
JAK2	ARL11	psi-mi:“MI:0915”(physical association)	0.370
ARL11	SMARCB1	psi-mi:“MI:0915”(physical association)	0.370
ARL11	SELENBP1	psi-mi:“MI:0914”(association)	0.350
CDKN1B	YKT6	psi-mi:“MI:0914”(association)	0.350
ARL11	NMT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (51): ARL11 (Two-hybrid), SESTD1 (Affinity Capture-MS), MTMR8 (Affinity Capture-MS), SENP1 (Affinity Capture-MS), SELENBP1 (Affinity Capture-MS), ARL11 (Two-hybrid), ARL11 (Two-hybrid), SESTD1 (Affinity Capture-MS), MTMR8 (Affinity Capture-MS), SENP1 (Affinity Capture-MS), ARL11 (Affinity Capture-MS), DDX19B (Affinity Capture-MS), NMT2 (Affinity Capture-MS), LLGL1 (Affinity Capture-MS), TSEN2 (Affinity Capture-MS)

ESM2 similar proteins: A1E2I4, A7VK00, B0BMZ3, E9PW74, F4HT21, G3MZQ6, G3X987, O81025, P0DJR0, P18588, P18589, P18590, P36406, P36407, P52333, P54120, P97343, Q2EMV9, Q4ADG7, Q4KLG2, Q501S4, Q5RCY1, Q62137, Q63272, Q63285, Q75N62, Q8BGX0, Q8BV66, Q8K3K9, Q8K3L6, Q8ND71, Q8NHV1, Q8TAS1, Q969Q4, Q99JY3, Q9BDB7, Q9BW83, Q9C8U2, Q9C8U5, Q9C8U6

Diamond homologs: A1CRG9, A1D4D1, A3LTA2, A8INQ0, A8ISN6, B5FYQ0, H2L0N8, O04266, O04267, O04834, O08697, O45379, P0C950, P0C951, P0CM16, P0CM17, P0CR30, P0CR31, P20606, P22274, P25160, P36404, P36405, P36536, P37996, P49703, P52885, P56559, P61208, Q01474, Q01475, Q02804, Q06849, Q09767, Q0CUN7, Q0VC18, Q10943, Q13795, Q19705, Q1MTE5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	39
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
147435	GRCh38/hg38 13q14.2-14.3(chr13:48307302-50927473)x1	Pathogenic
443381	GRCh37/hg19 13q14.2-14.3(chr13:47312129-51342279)x1	Pathogenic
545122	NC_000013.11:g.46968080_87381985del40413906	Pathogenic

SpliceAI

178 predictions. Top by Δscore:

Variant	Effect	Δscore
13:49628613:GAG:G	donor_gain	0.9900
13:49628613:GAGG:G	donor_loss	0.9800
13:49628614:AGGT:A	donor_loss	0.9800
13:49628615:GGT:G	donor_loss	0.9800
13:49628617:T:A	donor_loss	0.9700
13:49628613:G:GT	donor_gain	0.9600
13:49628616:G:GG	donor_gain	0.9600
13:49630424:CCCTA:C	acceptor_loss	0.9300
13:49630425:CCTA:C	acceptor_loss	0.9300
13:49630427:TA:T	acceptor_loss	0.9300
13:49630428:A:AC	acceptor_loss	0.9300
13:49630428:AG:A	acceptor_gain	0.9100
13:49630429:GG:G	acceptor_gain	0.9100
13:49628472:G:GT	donor_gain	0.9000
13:49630428:A:AG	acceptor_gain	0.9000
13:49630429:G:GG	acceptor_gain	0.9000
13:49628611:CAGAG:C	donor_gain	0.8400
13:49630427:TAGGA:T	acceptor_gain	0.8400
13:49630115:C:G	donor_gain	0.8300
13:49628604:A:AG	donor_gain	0.8200
13:49628605:G:GG	donor_gain	0.8200
13:49628612:AGAG:A	donor_gain	0.7700
13:49628608:A:AG	donor_gain	0.7600
13:49630820:G:GT	donor_gain	0.7200
13:49628582:G:GT	donor_gain	0.7100
13:49628614:AG:A	donor_gain	0.7000
13:49628615:GG:G	donor_gain	0.7000
13:49630429:GGA:G	acceptor_gain	0.7000
13:49630861:GC:G	donor_gain	0.6700
13:49630413:T:A	acceptor_loss	0.6400

AlphaMissense

1263 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:49630524:C:T	T26I	0.991
13:49630583:T:C	F46L	0.990
13:49630585:C:A	F46L	0.990
13:49630585:C:G	F46L	0.990
13:49630522:G:C	K25N	0.988
13:49630522:G:T	K25N	0.988
13:49630816:G:C	K123N	0.987
13:49630816:G:T	K123N	0.987
13:49630520:A:C	K25Q	0.984
13:49630521:A:C	K25T	0.984
13:49630635:A:C	D63A	0.982
13:49630521:A:T	K25M	0.981
13:49630815:A:C	K123T	0.981
13:49630634:G:C	D63H	0.978
13:49630520:A:G	K25E	0.977
13:49630635:A:G	D63G	0.977
13:49630715:A:C	S90R	0.977
13:49630717:C:A	S90R	0.977
13:49630717:C:G	S90R	0.977
13:49630815:A:T	K123M	0.970
13:49630635:A:T	D63V	0.969
13:49630660:A:C	R71S	0.969
13:49630660:A:T	R71S	0.969
13:49630636:C:A	D63E	0.967
13:49630636:C:G	D63E	0.967
13:49630669:G:C	W74C	0.967
13:49630669:G:T	W74C	0.967
13:49630502:G:C	G19R	0.966
13:49630813:C:A	N122K	0.966
13:49630813:C:G	N122K	0.966

dbSNP variants (sampled 300 via entrez): RS1000262385 (13:49628502 G>T), RS1000647150 (13:49628732 C>T), RS1000761441 (13:49628482 AAGG>A), RS1001383569 (13:49627119 C>G), RS1002677055 (13:49626795 T>C,G), RS1002862583 (13:49627285 G>A), RS1003043769 (13:49632921 C>G,T), RS1003067862 (13:49632513 G>T), RS1003091813 (13:49629872 A>G), RS1004147630 (13:49631474 T>G), RS1004498019 (13:49631735 G>A), RS1004615876 (13:49629053 C>T), RS1005229904 (13:49628241 G>A,C), RS1006220844 (13:49626535 A>C), RS1006230791 (13:49626983 T>C)

Disease associations

OMIM: gene MIM:609351 | disease phenotypes: MIM:613884

GenCC curated gene-disease

Disease	Classification	Inheritance
hereditary neoplastic syndrome	Limited	Autosomal dominant

Mondo (2): chromosome 13q14 deletion syndrome (MONDO:0013481), hereditary neoplastic syndrome (MONDO:0015356)

Orphanet (1): Monosomy 13q14 syndrome (Orphanet:1587)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001860_4	Multiple sclerosis	3.000000e-07
GCST010002_186	Refractive error	1.000000e-36
GCST011096_30	Systemic lupus erythematosus	4.000000e-08
GCST90011866_19	Systemic lupus erythematosus	1.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
C535484	13q deletion syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
CGP 52608	affects binding, increases reaction	1
clothianidin	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Ethyl Methanesulfonate	increases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression	1
Silicon Dioxide	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

29 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001496	Not specified	COMPLETED	Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001898	Not specified	COMPLETED	Microarray Analysis for Human Genetic Disease
NCT00026884	Not specified	RECRUITING	Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT02289326	Not specified	COMPLETED	Biomarker Monitoring in TP53 Mutation Carriers
NCT02958462	Not specified	RECRUITING	Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT03160274	Not specified	RECRUITING	Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
NCT03426878	Not specified	COMPLETED	Cancer Health Assessments Reaching Many
NCT03857594	Not specified	ACTIVE_NOT_RECRUITING	Integrative Sequencing In Germline and Hereditary Tumours
NCT03973450	Not specified	UNKNOWN	Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
NCT03979612	Not specified	UNKNOWN	Evaluation of the Adhesion to the GENEPY Network
NCT04261972	Not specified	ACTIVE_NOT_RECRUITING	Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04494945	Not specified	RECRUITING	Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT04541654	Not specified	RECRUITING	Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT04763915	Not specified	ACTIVE_NOT_RECRUITING	Improving Care After Inherited Cancer Testing
NCT05562778	Not specified	RECRUITING	Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
NCT05664867	Not specified	RECRUITING	Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)
NCT05721326	Not specified	COMPLETED	Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
NCT06096688	Not specified	RECRUITING	Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06654466	Not specified	RECRUITING	Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
NCT06708429	Not specified	RECRUITING	Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06726642	Not specified	RECRUITING	CfDNA in Hereditary And High-risk Malignancies 2
NCT06914726	Not specified	ENROLLING_BY_INVITATION	Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
NCT06927947	Not specified	RECRUITING	Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
NCT06999954	Not specified	RECRUITING	Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
NCT07052266	Not specified	RECRUITING	Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening
NCT07195071	Not specified	RECRUITING	Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening
NCT07378423	Not specified	RECRUITING	Questionnaire on Congenital Cancer Signs Through Self-Assessment
NCT07381985	Not specified	ENROLLING_BY_INVITATION	Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
NCT07542405	Not specified	NOT_YET_RECRUITING	A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families